Laekna, Inc. Advances Obesity Drug LAE102 with U.S. FDA Submission

The latest announcement is out from Laekna, Inc. ( (HK:2105) ).

Laekna, Inc. has announced the submission of an Investigational New Drug amendment to the U.S. FDA for its obesity treatment drug, LAE102. This development follows an IND approval in April 2024 and a clinical collaboration with Eli Lilly to accelerate global clinical trials. The U.S. Phase 1 Clinical Trial is set to begin in the second quarter of 2025, with Eli Lilly responsible for execution and funding. LAE102 has shown promise in pre-clinical models for increasing lean mass and reducing fat mass, positioning it as a potential novel treatment for obesity.

More about Laekna, Inc.

Laekna, Inc. is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. It focuses on developing precision therapies, with a particular emphasis on treatments for obesity. The company’s primary product in this area is LAE102, a monoclonal antibody targeting ActRIIA, involved in muscle regeneration and lipid metabolism.

YTD Price Performance: 55.18%

Average Trading Volume: 6,974,458

Technical Sentiment Signal: Strong Sell

Find detailed analytics on 2105 stock on TipRanks’ Stock Analysis page.